Literature DB >> 17933034

Tyrosine kinase inhibitors for chronic myelogenous leukemia.

Alfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17933034

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction.

Authors:  Wei-Gang Tong; Hagop Kantarjian; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Gautam Borthakur; Jianqin Shan; Sherry Pierce; Mary Beth Rios; Jorge Cortes
Journal:  Cancer       Date:  2010-07-01       Impact factor: 6.860

Review 2.  Imatinib and beyond--exploring the full potential of targeted therapy for CML.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes
Journal:  Nat Rev Clin Oncol       Date:  2009-08-04       Impact factor: 66.675

3.  Complex variant of Philadelphia translocation involving chromosomes 9, 12, and 22 in a case with chronic myeloid leukaemia.

Authors:  F Malvestiti; C Agrati; S Chinetti; A Di Meco; S Cirrincione; M Oggionni; B Grimi; F Maggi; G Simoni; F R Grati
Journal:  Case Rep Genet       Date:  2014-06-18

Review 4.  Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy?

Authors:  Alfonso Quintás-Cardama; Jorge Cortes
Journal:  Curr Oncol Rep       Date:  2009-09       Impact factor: 5.075
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.